[HTML][HTML] Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated …
IP Naya, L Tombs, DA Lipson, C Compton - Advances in Therapy, 2018 - Springer
Introduction Assessing clinically important measures of disease progression is essential for
evaluating therapeutic effects on disease stability in chronic obstructive pulmonary disease
(COPD). This analysis assessed whether providing additional bronchodilation with the long-
acting muscarinic antagonist umeclidinium (UMEC) to patients treated with inhaled
corticosteroid (ICS)/long-acting β 2-agonist (LABA) therapy would improve disease stability
compared with ICS/LABA therapy alone. Methods This integrated post hoc analysis of four …
evaluating therapeutic effects on disease stability in chronic obstructive pulmonary disease
(COPD). This analysis assessed whether providing additional bronchodilation with the long-
acting muscarinic antagonist umeclidinium (UMEC) to patients treated with inhaled
corticosteroid (ICS)/long-acting β 2-agonist (LABA) therapy would improve disease stability
compared with ICS/LABA therapy alone. Methods This integrated post hoc analysis of four …
[引用][C] Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting b2-Agonist Therapy: An Integrated …
IPNLT David, ALC Compton - Adv Ther, 2018
以上显示的是最相近的搜索结果。 查看全部搜索结果